TriangleNCT00354744 · OUTCOME
Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From enrollment to up to 2 years
What was measured
Adverse events are reported for patients receiving concurrent irinotecan hydrochloride and radiotherapy.
Analysis population: Percentage of patients experiencing a grade 3/4/5 toxicity in a course.
Groups in this outcome
High_Risk_Rhabdomyosarcoma
Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
| Group | Source count |
|---|---|
| High_Risk_Rhabdomyosarcoma | 109 |
Reported measurements
Course 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| High_Risk_Rhabdomyosarcoma | 53.3 | Not reported | 43.4 | 63.0 | Not reported |
Course 2
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| High_Risk_Rhabdomyosarcoma | 68.4 | Not reported | 58.2 | 77.4 | Not reported |
Course 3
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| High_Risk_Rhabdomyosarcoma | 79.3 | Not reported | 69.3 | 87.3 | Not reported |
Course 4
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| High_Risk_Rhabdomyosarcoma | 55.7 | Not reported | 43.3 | 67.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 43.4
- upper Limit
- 63.0
- value
- 53.3
- title
- Course 1
- categories
- measurements
- group Id
- OG000
- lower Limit
- 58.2
- upper Limit
- 77.4
- value
- 68.4
- title
- Course 2
- categories
- measurements
- group Id
- OG000
- lower Limit
- 69.3
- upper Limit
- 87.3
- value
- 79.3
- title
- Course 3
- categories
- measurements
- group Id
- OG000
- lower Limit
- 43.3
- upper Limit
- 67.6
- value
- 55.7
- title
- Course 4
- denoms
- counts
- group Id
- OG000
- value
- 109
- units
- Participants
- description
- Adverse events are reported for patients receiving concurrent irinotecan hydrochloride and radiotherapy.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
- id
- OG000
- title
- High_Risk_Rhabdomyosarcoma
- param Type
- NUMBER
- population Description
- Percentage of patients experiencing a grade 3/4/5 toxicity in a course.
- reporting Status
- POSTED
- time Frame
- From enrollment to up to 2 years
- title
- Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy
- type
- PRIMARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice